Pharmaceutical industry
The total control of drug development by pharmaceutical companies is both problematic and unsustainable. Pharmaceutical companies are often more concerned about profits than public health priorities or corporate accountability. As a result, key health priorities are neglected and people lack access to the medicine they need. Companies engage in harmful and unethical research practices, and irresponsible marketing practices. SOMO researches the policies and practices around pharmaceutical drug development, with a particular focus on the ethics of drug testing in low and middle income countries. Clinical trials in these countries often involve vulnerable people, raising serious ethical questions. We push pharmaceutical companies to act with due diligence in line with the UN Guiding Principles on Business and Human Rights in relation to peoples’ participation in clinical trials, as well as Post-Trial Access (PTA) to medicine.
Overview of articles
-
Overpriced Published on:
Irene SchipperPosted in category:Publication
Irene Schipper -
Affordable medication leaves biggest Dutch insurers coldPosted in category:News
Gerhard SchuilPublished on: -
Taming big Pharma Published on:
Joseph Wilde-RamsingPosted in category:Publication
Joseph Wilde-Ramsing
-
Position on supplementary protection certificates for medicinal productsPosted in category:Published on:Statement
-
-
Organisations call for greater social impact of the European Commission’s medical research and innovation investmentsPosted in category:Published on:Statement
-
Ethical verification of clinical trials on medication must be more stringentPublished on:Posted in category:Opinion
-
Roche intimidates clinical drug trial participant following reportPosted in category:NewsPublished on: -
Egyptian patients targeted in clinical drugs trials from which they do not benefitPosted in category:NewsPublished on:
-
Industry-sponsored clinical drug trials in Egypt Published on:
Irene SchipperPosted in category:Publication
Irene Schipper
-
-
Post-trial access to treatment Published on:
Irene SchipperPosted in category:Publication
Irene Schipper
-
-
-
Better protection of clinical trial participants in low income countries?Posted in category:NewsPublished on: -
